Technology Bundle ID

Diagnostic and Therapeutic Use of Brother of the Regulator of Imprinted Sites (BORIS) Alternative Splice Forms

Linked ID
Lead Inventors
Victor Lobanenkov (NIAID)
Development Status
The technology is currently in the pre-clinical stage of development.
Disease Areas
This technology identifies twenty five (25) new alternatively spliced transcripts of the BORIS gene. The transcripts lead to the expression of seventeen different protein isoforms with variable N- and C-termini encoded by BORIS gene locus. Differential expression levels of BORIS isoforms were observed in different cancers. While some BORIS alternative splice variants were expressed at different levels in all types of cancers, other expressed forms are specific to particular cancer(s).
Commercial Applications
  • Simple, rapid, RT-PCR based diagnostic test to detect BORIS isoforms in cancer patients.
  • Profiling of BORIS splice variants can be useful as a diagnostic tool for the detection of cancers.
  • BORIS can be a therapeutic target antigen for immunotherapeutic and/or siRNA based treatments for cancer.
  • BORIS can be used in combination with other established immunogens for immunotherapeutic treatment of several cancers.

Request More Info